RESEARCH

Effect of Amlodipine/Nebivolol combination therapy on central BP and PWV compared to Amlodipine/Valsartan combination therapy

El-Zahraa M. Sultan¹*, Hoda Rabea², Ahmed A. Elberry³ and Hesham B. Mahmoud⁴

Abstract

Background: Pulse wave velocity (PWV) and central blood pressure (CBP) have been introduced into management of hypertensive patients. PWV is positively correlated with arterial wall stiffness while central aortic pressure becomes better predictor of cardiovascular outcome than peripheral pressure. Reduction in CBP provides protective properties against subclinical organ damage. This work aims to investigate the effect of a new combination therapy of Amlodipine/Nebivolol (A/N) on central BP, peripheral BP and PWV. The results of using this combination will be compared to the well-established fixed-dose combination of Amlodipine/Valsartan (A/V). The study conducted between October 2018 and August 2020. One hundred and two hypertensive patients were assigned for Amlodipine 10 mg/Valsartan 160 mg combination therapy (A/V, n = 52) or Amlodipine 10 mg/Nebivolol 5 mg combination therapy (A/N, n = 50) by simple 1:1 randomization. Office, central blood pressure and PWV were measured on first (0 week), second (4–8 weeks) and third visit (10–12). Difference in BP (in each arm and between arms) was calculated along all visits.

Results: No statistical significant difference was found between A/V and A/N regarding age, gender, BMI and CV history. OBP, CBP and PWV were significantly reduced in each arm, but no differences were found when comparing both arm results to each other. Recorded side effects were insignificant.

Conclusions: The new combination therapy Amlodipine/Nebivolol (A/N) affords a significant reduction in CBP, PBP and PWV with minor and tolerable side effects. It has provided comparable results to Amlodipine/Valsartan (A/V) combination therapy.

Keywords: Amlodipine/Nebivolol, Amlodipine/Valsartan, Combination therapy, Hypertension, Central blood pressure, Arterial stiffness

Background

Central aortic pressure (CBP) becomes a better predictor of cardiovascular outcome than peripheral pressure, particularly in individuals with prominent pulse pressure (PP) amplification [1, 2]. Reduction in CBP by some antihypertensive drugs provides protective properties against subclinical organ damage [3]. CBP was initially measured directly by using invasive devices, and then, other methods have been established to assess central pressures based on analyses of carotid and radial pulses or carotid distension waves [4]. Pulse wave velocity (PWV) may predict the cardiovascular mortality and morbidity of hypertensive patients [5]. PWV becomes a marker for arterial stiffness and is associated with atherosclerosis of the aorta. Higher arterial PWV values represent greater stiffness. Its monitoring through a noninvasive method is a useful way of evaluating the degree of atherosclerosis and predicting all-cause and cardiovascular mortality [6]. According to previous data [7, 8], some antihypertensive medications have been shown to influence arterial stiffness with different degrees of effect. This work aims to...
investigate the effect of a new combination of Amlodipine/Nebivolol (A/N) on central BP and PWV compared to the well-established fixed-dose combination of Amlodipine/Valsartan (A/V).

**Methods**

This is a prospective open-label randomized study which aims to investigate the effect of Amlodipine 10 mg/Nebivolol 5 mg (A/N) combination therapy in comparison with Amlodipine 10 mg/Valsartan 160 mg (A/V) on central hemodynamics parameters. The study was conducted in a hypertension clinic in hospital between October 2018 and August 2020. All moderate to severe adult hypertensive patients were included. Patients with contraindication to Amlodipine, Valsartan and Nebivolol or pregnant, lactating women or females of child-bearing potential not practicing contraception were excluded. The included hypertensive patients were either newly diagnosed or previously received antihypertensive medications and still with uncontrolled hypertension (Table 1). Antihypertensive medications were substituted with either of the suggested combination through the randomization process. Patients were randomized by stratifying according to age (≥ 55 years old) and sex then by simple 1:1 randomization. One hundred and twenty-eight hypertensive patients were assigned for Amlodipine 10 mg/Valsartan 160 mg combination therapy (A/V) or Amlodipine 10 mg/Nebivolol 5 mg combination therapy (A/N). Twenty-six patients were excluded over follow-up visits (Fig. 1). Statistical analysis was applied on the final number of patients; one hundred and two patients, divided as: 52 patients in A/V group and 50 patients in A/N group. Office, central blood pressure and hemodynamics parameters were measured on first (0 weeks), second (4–6 weeks) and third visit (10–12 weeks). Difference in BP (in each group and between groups) was calculated across the three separate visits. At the third visit, ambulatory blood pressure (AMBp) was done for patients with uncontrolled blood pressure to exclude white coat hypertension (WCH). Orthostatic hypotension, rash, headache were looked for as a side effects for treatments in follow-up visits.

Demographic data and past medical history collected. Assessment of hypertension-mediated organ damage was accomplished by 12-lead ECG, echocardiography, urine albumin-to-creatinine ratio and fundus examination.

### Table 1  Baseline patients’ characteristics

| Variable               | A/V [n = 52 (%)] | CI       | A/N [n = 50 (%)] | CI       | P value |
|------------------------|------------------|----------|------------------|----------|---------|
| **Demographic**        |                  |          |                  |          |         |
| Age (mean±SD) years    | 57.5 ± 10.7      | [54.5, 60.5] | 59.4 ± 10.4      | [56.4, 62.3] | 0.382   |
| Sex                    |                  |          |                  |          |         |
| Male                   | 18 (34.6)        |          | 19 (38.0)        |          | 0.722   |
| Female                 | 34 (65.4)        |          | 31 (62.0)        |          |         |
| BMI (mean±SD)          | 31.9 ± 5.0       | [30.5, 33.3] | 31.7 ± 6.1       | [30.0, 33.5] | 0.859   |
| **CV history**         |                  |          |                  |          |         |
| HTN                    |                  |          |                  |          |         |
| Chronic                | 49 (94.2)        |          | 48 (96.0)        |          | 0.679   |
| Naive                  | 3 (5.8)          |          | 2 (4.0)          |          |         |
| DM                     | 21 (40.4)        |          | 14 (28.0)        |          | 0.188   |
| Dyslipidemia           | 29 (55.8)        |          | 34 (68.0)        |          | 0.204   |
| Dyslip.TT              |                  |          |                  |          |         |
| Rosuvastatin           | 22 (42.3)        |          | 31 (62.0)        |          | 0.155   |
| Atorvastatin           | 8 (15.4)         |          | 5 (10.0)         |          |         |
| Atorvastatin/EZT       | 2 (3.8)          |          | 0 (0.0)          |          |         |
| No                     | 20 (38.5)        |          | 14 (28.0)        |          |         |
| AF                     | 7 (13.5)         |          | 6 (12.0)         |          | 0.825   |
| Smoking                |                  |          |                  |          |         |
| Smoker                 | 5 (9.6)          |          | 5 (10.0)         |          | 0.996   |
| Non-smoker             | 44 (84.6)        |          | 42 (84.0)        |          |         |
| Ex-smoker^             | 3 (5.8)          |          | 3 (6.0)          |          |         |

A/V, Amlodipine/Valsartan; A/N, Amlodipine/Nebivolol; BMI, body mass index, CV, cardiovascular; HTN, hypertension; TT, treatment; DM, diabetes mellitus; IHD, ischemic heart disease; AF, atrial fibrillation; Dyslip, dyslipidemia; EZT, ezetimibe

^Ex-smoker; smoking cessation ≥ 6 month

*A p-value less than or equal 0.05 is statistically significant
Echocardiography was performed for all patients in the left lateral position in multiple windows using PHILLIPS HD11 and VIVID S5 GE machine. Ejection fraction (EF), left ventricular (LV) dimensions, septal and posterior wall thickness and valvular affection were obtained. Diastolic dysfunction was also assessed. Albumin-to-creatinine ratio was used as a marker for nephropathy assessment. LVH was detected by ECG and echocardiography.

A/V combination is a single-pill combination was administrated on fixed daily dose, day or night, while A/N combination is a two-pill combination were administrated separately on fixed times. Amlodipine 10 mg is administrated at day time while Nebivolol 5 mg is administrated at night.

Diagnosis, patient’s inclusion and follow-up visits depended on office blood pressure readings. Three office blood pressure measurements were obtained by properly calibrated mercury sphygmomanometer at each visit by the same operator. A standard operating procedure for measuring BP was followed [9–11]. For each patient,
BP was measured twice at 30-s intervals. Central blood pressure was measured by the Mobil-O-Graph®—the 24-h PWA Monitor calibrated device [12]. Measurement range of this device is 60–290 mmHg for systolic and 30–195 mmHg for diastolic blood pressure, pressure range (0 to 300 mmHg) and pulse range (30–240 bpm). The device uses an oscillometric method and its accuracy level is ±3 mmHg. The device measures the brachial systolic and diastolic blood pressure, and then, the cuff re-inflates at the level of the diastolic blood pressure for approximately 10 s. The sensor records brachial pressure waveforms. An aortic pulse wave is then derived by using a generalized transfer function. Several pressure and cardiovascular parameters including Alx are computed by using the ARCSolver algorithm [13].

**Statistical analysis**

Data were analyzed using the software, Statistical Package for Social Science (SPSS Inc. Released 2009, PASW Statistics for Windows, version 18.0: SPSS Inc., Chicago, Illinois, USA). Frequency distribution, as a percentage and descriptive statistics in the form of mean and standard deviation, was calculated. Chi-square, t-test and correlations were done in order to compare the two groups in relation to age, gender, BMI, HTN, DM, dyslipidemia, AF and smoking. P values of less than 0.05 were considered significant.

**Results**

We tested data normality before conducting the analysis, and the data were normally distributed.

**Baseline data**

**Demographic data and patients’ characteristics**

Baseline patients’ characteristics were comparable between both groups. No statistical significant difference was found between A/V and A/N regarding age, gender, BMI and CV history (Table 1).

**Echocardiographic baseline data**

Echocardiographic baseline data in both groups showed no statistically significant difference (Table 2). Ejection fraction and myocardium dimension were normal in both A/V and A/N groups. Diastolic dysfunction (DD) was higher in A/N group; P = 0.006.

**Target organ damage baseline and laboratory investigations**

No statistically significant difference was found between groups regarding target organ damage (TOD), left ventricular hypertrophy (LVH), retinopathy, stroke and nephropathy. P values are illustrated in Table 2. Mean values of CH, TG, LDL and HDL did not show statistically significant difference in both A/V and A/N; P = 0.355, P = 0.808, P = 0.786 and P = 0.505. Al/Cr ratio and fundus examination also did not show significant difference in both groups (Table 2).

**Baseline blood pressure**

Office blood pressure (OBP) and CBP had no statistically significant difference between both groups. Mean OBP value was 158.3 ± 15.0/99.9 ± 8.4 in A/V vs. 154.7 ± 12.3/97.7 ± 6.1 in A/N (Table 3). Mean value of CBP was 135.9 ± 14.7/93.6 ± 11.4 in A/V and 135.2 ± 11.3/91.5 ± 9.5 in A/N. PBP was not statistically significant in both groups. PWV, AIX, HR and PP were not statistically different; P = 0.443, P = 0.236, P = 0.039 and P = 0.730, Table 3.

**After treatment data**

**Changes in blood pressure between visits (baseline, second and third)**

i. **Office Blood Pressure (OBP)**

| Table 2 Baseline investigations and target organ damage |
|--------------------------------------------------------|
| A/V [n = 52 (%)] | A/N [n = 50 (%)] | P value |
|------------------|------------------|---------|
| **Investigations** |                  |         |
| Lipid profile    |                  |         |
| CH               | 179.7 ± 43.7     | 171.7 ± 43.7 | 0.355 |
| TG               | 145.3 ± 57.5     | 148.0 ± 57.2 | 0.808 |
| LDL              | 106.2 ± 39.1     | 104.3 ± 32.5 | 0.786 |
| HDL              | 49.6 ± 17.52     | 52.2 ± 22.0  | 0.505 |
| AL/Cr            | 49.7 ± 120.3     | 41.6 ± 116.3 | 0.729 |
| Fundus examination\* |              |         |
| G0               | 49 (94.2)        | 44 (88.0)  | 0.464 |
| G1               | 2 (3.8)          | 2 (4.0)    |       |
| G2               | 1 (1.9)          | 2 (4.0)    |       |
| G3               | 0 (0.0)          | 2 (4.0)    |       |
| Echocardiographic data |                |         |
| EF % (mean ± SD) | 64.2 ± 5.9       | 64.1 ± 6.5 | 0.954 |
| IVS              | 1.0 ± 0.1        | 1.0 ± 0.1  | 0.712 |
| PWT              | 1.0 ± 0.4        | 1.1 ± 0.7  | 0.442 |
| Target organ damage |                |         |
| LVH              | 10 (19.2)        | 9 (18.0)   | 0.873 |
| Retinopathy      | 3 (5.8)          | 6 (12.0)   | 0.267 |
| Stroke           | 1 (1.9)          | 0 (0.0)    | 0.324 |
| Nephropathy      | 7 (13.5)         | 5 (10.0)   | 0.588 |

\* Fundus examination Grades: G0: No visible abnormalities, G1: Diffuse arteriolar narrowing, G2: G1 + focal arteriolar constriction, G3: G2 + retinal hemorrhage

A/V, Amlodipine/Valsartan; A/N, Amlodipine/Nebivolol; CH, total cholesterol; TG, triglycerides; LDL, low-density lipoprotein; HDL, high-density lipoprotein; AL/Cr, albumin-to-creatinine ratio; EF, ejection fraction; IVS, intraventricular septum; PWT, posterior wall thickness; LA, left atrium; DD, diastolic dysfunction; LVH, left ventricular hypertrophy

**Office Blood Pressure (OBP)**

| Investigations | A/V [n = 52 (%)] | A/N [n = 50 (%)] | P value |
|----------------|-----------------|-----------------|---------|
| CH             | 179.7 ± 43.7    | 171.7 ± 43.7    | 0.355   |
| TG             | 145.3 ± 57.5    | 148.0 ± 57.2    | 0.808   |
| LDL            | 106.2 ± 39.1    | 104.3 ± 32.5    | 0.786   |
| HDL            | 49.6 ± 17.52    | 52.2 ± 22.0     | 0.505   |
| AL/Cr          | 49.7 ± 120.3    | 41.6 ± 116.3    | 0.729   |
| Fundus examination\* |        |                 |         |
| G0             | 49 (94.2)       | 44 (88.0)       | 0.464   |
| G1             | 2 (3.8)         | 2 (4.0)         |         |
| G2             | 1 (1.9)         | 2 (4.0)         |         |
| G3             | 0 (0.0)         | 2 (4.0)         |         |
| Echocardiographic data |         |                 |         |
| EF % (mean ± SD) | 64.2 ± 5.9     | 64.1 ± 6.5      | 0.954   |
| IVS            | 1.0 ± 0.1       | 1.0 ± 0.1       | 0.712   |
| PWT            | 1.0 ± 0.4       | 1.1 ± 0.7       | 0.442   |
| Target organ damage |         |                 |         |
| LVH            | 10 (19.2)       | 9 (18.0)        | 0.873   |
| Retinopathy    | 3 (5.8)         | 6 (12.0)        | 0.267   |
| Stroke         | 1 (1.9)         | 0 (0.0)         | 0.324   |
| Nephropathy    | 7 (13.5)        | 5 (10.0)        | 0.588   |

\*Fundus examination Grades: G0: No visible abnormalities, G1: Diffuse arteriolar narrowing, G2: G1 + focal arteriolar constriction, G3: G2 + retinal hemorrhage

A/V, Amlodipine/Valsartan; A/N, Amlodipine/Nebivolol; CH, total cholesterol; TG, triglycerides; LDL, low-density lipoprotein; HDL, high-density lipoprotein; AL/Cr, albumin-to-creatinine ratio; EF, ejection fraction; IVS, intraventricular septum; PWT, posterior wall thickness; LA, left atrium; DD, diastolic dysfunction; LVH, left ventricular hypertrophy

A/V, Amlodipine/Valsartan; A/N, Amlodipine/Nebivolol; CH, total cholesterol; TG, triglycerides; LDL, low-density lipoprotein; HDL, high-density lipoprotein; AL/Cr, albumin-to-creatinine ratio; EF, ejection fraction; IVS, intraventricular septum; PWT, posterior wall thickness; LA, left atrium; DD, diastolic dysfunction; LVH, left ventricular hypertrophy
OBP difference between all visits showed no statistically significant difference between both groups; \( P_{\text{sys}} = 0.168 \) and \( P_{\text{dys}} = 0.936 \), Tables 3 and 4. However, difference between (Sys2−Sys1/dys2−dys1), (Sys3−Sys2/ dys3−dys2) and (Sys3−Sys1/dys3−dys1) was statistically significant within each group (Fig. 2).

**ii. Central Blood Pressure (CBP)**

CBP difference between all visits did not reveal statistically significant difference between A/V and A/N group; \( P_{\text{sys}} = 0.331 \) and \( P_{\text{dys}} = 0.318 \). For each group, reduction in CBP in every visit was statistically significant compared to the previous one (Fig. 2, Table 4).

Reduction in HR was statistically significant only in A/N group; \( P \) value of HR 3−HR 1 = 0.017. No statistical difference was found regarding PP between both groups; \( P = 0.155 \) (Fig. 3).

**Changes in central hemodynamics between visits (baseline, second and third)**

Difference in PWV was not significant between groups; \( P = 0.379 \), while difference within A/N group was statistically significant \( (P \) value of PWV 2−PWV 1 = 0.000), \( (P \) value of PWV 3−PWV 2 = 0.003) and \( (P \) value of PWV 3−PWV 1 = 0.000) (Fig. 3). AIX also did not show a significant difference between groups; \( P = 0.803 \). AIX difference within A/N group \( (\text{AIX 3−AIX 2}) \) and \( (\text{AIX 3−AIX 1}) \) was statistically significant; \( P = 0.003 \) and \( P = 0.000 \) (Fig. 3).

**Safety monitoring during treatment**

In A/N, 6 patients had lower limb edema. One patient had headache and no cases of rash were reported. Eight patients in A/V had lower limb edema; two patients had headache and no rash cases were reported.

**Excluded patients during the study**

Across the three follow-up visits, 15 patients were excluded from A/N group and 11 from A/V group, due to lack of patient compliance to treatment or because

### Table 3 Central and peripheral blood pressure at each visit

|          | A/V \((n = 52 \%)\) | A/N \((n = 50 \%)\) |
|----------|---------------------|---------------------|
| Systole  | Diastole            | Systole  | Diastole            |
| OBP      |                     |         |                     |
| 1st      | 158.3 ± 15.0        | 154.7 ± 12.3 | 99.9 ± 8.4          | 97.7 ± 6.1          |
|          | [145.1, 160.3]      | [151.2, 158.4] | [97.5, 102.2]       | [95.9, 99.4]        |
| 2nd      | 153.9 ± 11.2        | 134.6 ± 10.3 | 84.7 ± 7.3          | 83.8 ± 7.8          |
| 3rd      | 126.1 ± 8.8         | 123.1 ± 10.0 | 78.6 ± 6.8          | 79.0 ± 7.8          |

### Table 4 Difference in BP over follow-up visits

| Difference in BP | AV | CI | AN | CI | \( P \) wave |
|------------------|----|----|----|----|--------------|
| OBP Sys3−Sys1    | −32.1 | −37.1 | −27.2 | −31 | −34.5 | −27.4 | 0.168   |
| OBP Dys3−Dys1    | −21.2 | −24.2 | −18.2 | −18.5 | −21.2 | −15.8 | 0.036   |
| CBP Sys3−Sys1    | −22.5 | −27.1 | −17.8 | −20.8 | −25.2 | −16.5 | 0.331   |
| CBP Dys3−Dys1    | −14.8 | −18.3 | −11.2 | −12.3 | −15.5 | −9.1  | 0.318   |

A/V, Amlodipine/Valsartan; A/N, Amlodipine/Nebivolol; OBP, office blood pressure; CBP, central BP; 1st, first visit without medications (A/V or A/N); 2nd, second visit (on either A/V or A/N); 3rd, visit (on either A/V or A/N).

![](image.png)
they had already started taking other medications such as NSAID or alpha-agonist drugs.

Discussion
To our knowledge, this is the first study to address the safety and efficacy of Amlodipine/Nebivolol (A/N) combination itself or to compare it with the well-established combination of Amlodipine/Valsartan (A/V). BP reduction in hypertensive patients is associated with a lower rate of cardiovascular events[12]. Combination of A/N showed significant reduction of office and central BP through all visits ($P=0.000$) (Table 3). Central BP reduction was accompanied with decrease in PWV over the second and third visit. This result is attributed to the combined vasodilatory effect of Amlodipine with Nebivolol through releasing nitric oxide and improving the endothelial function, which reduces arterial stiffness (AS) [8]. Long-term use of Nebivolol showed promising results regarding CBP and AS compared to other b-blockers [13–17]. Rather than Nebivolol, other types of B-blocker were inferior compared to ARBs [18]. Significant effect of Amlodipine on brachial and central BP was obtained within A/V group, while patients in A/N group had comparable results to those in A/V group regarding OBP, CBP and PWV (Figs. 2, 3). CBP difference (Sys3-1/Dys3-1) in A/V was $-22.5 \pm 16.6/-14.8 \pm 12.8$ mmHg vs. $-20.8 \pm 15.0/-12.3 \pm 11.0$ mmHg in A/N group.

Target OBP ($<140/90$) was not obtained in four patients in A/N group versus five patients in A/V group (140/80, 140/80, 140/85 and 150/100 vs. 140/80, 140/85, 140/85, 150/80 and 160/90). Ambulatory blood pressure (AMBP) was done for those patients to exclude white coat hypertension (WCH); this revealed two patients with white coat hypertension in A/N versus one patient in A/V group. Patients with WCH in the A/N group had uncontrolled AMBP during night times only. This result could be attributed to the morning administration of Amlodipine instead of night administration. Flack et al. [23] had discussed the effect of single daily antihypertensive drug in comparison with twice daily administration on blood pressure variability. This study concluded that long acting drugs provided high trough-to-peak ratio which allowed better BP control during the nighttime and early morning hours. This eliminates the need to use high dose of short acting drugs to obtain high trough-to-peak ratio; this will lead to fewer adverse events. The timing of the drug administration also can affect the early morning surge in BP which eventually decreases the blood pressure variability. Theoretically, A/N could have intermediate to high trough-to-peak ratio; however, Amlodipine has longer duration of action than Nebivolol. Night administration of Amlodipine would be contributed to better coverage until early morning.

PWV values are affected by aging process [24, 25], impaired Glucose level [26], obesity [27] and smoking [28, 29], but not by gender which agrees with previously published studies. Both A/V and A/N revealed no difference in baseline age or gender ($P=0.382$ and $P=0.722$). Diabetes, dyslipidemia, BMI and smoking status are comparable in both groups. Patients on A/N combination had significant reduction in PWV; this was revealed through the three follow-up visits ($P=0.000$) with no final statistical difference in comparison with those on A/V ($P=0.379$).

Using AIx as a co-marker for AS [30, 31]) in hypertensive patients could provide more knowledge about patient vascular aging in status versus the real biological aging. In our study, AIx decreased over the second and the third visit in each group with no statistical difference between both groups ($P=0.0803$).

Reduction in HR was significant only within A/N patients ($P=0.017$), but not between both groups ($P=0.155$). Baseline HR was not statistically different.
between both groups; A/V HR = 80.8 ± 14.5 and A/N HR = 74.9 ± 14.2 (P = 0.039).

Increased PP is a significant risk factor for development of heart disease and vital organ damage especially the brain and the kidneys; a 10 mmHg increase in the pulse pressure raises the cardiovascular risk by as much as 20% [32]. Wide PP (> 100 mmHg) is associated with extensive cardiovascular disease and is an independent predictor of disease progression and all-cause mortality [33–35]. Values of baseline PP in both groups A/V and A/N were not wide (53.7 ± 191.1 and 55.2 ± 18.0; P = 0.730). PP values were decreased significantly within A/N over the three follow-up visits, but not in A/V group (P = 0.002) vs. (P = 0.234) (Fig. 3).

A/N combination had a low rate of minor side effects such as lower limb edema and headache as in A/V group. Orthostatic hypotension was reported in three elderly patients in A/N group at the second week after starting the treatment and disappeared in the following visits. This could be attributed to the combined vasodilatory effect of Nebivolol and Amlodipine.

**Future directs**
A/N combination would be investigated in hypertensive patients with ischemic heart disease or heart failure with preserved ejection fraction.

**Limitations**
Since A/N is a newly proposed fixed-dose combination therapy which is not available in the form of a single-pill combination, Nebivolol 5 mg and Amlodipine 10 mg were administrated as two pills. The administration time of both pills is fixed through the day, but it may be affected by patient commitment and compliance at home, which may impact the timing of the two drugs release throughout the day. Finally, the single-center trial was another limitation; larger sample size and multicenter trials are needed to provide more comprehensive results.

**Conclusions**
The new combination therapy Amlodipine/Nebivolol (A/N) affords a significant reduction in CBP, PBP and PWV with minor and tolerable side effects. It has provided comparable results to the well-known Amlodipine/Valsartan (A/V) combination therapy.

**Abbreviations**
AMBP: Ambulatory blood pressure; A/V: Amlodipine 10 mg/Valsartan 160 mg; A/N: Amlodipine 10 mg/Nebivolol 5 mg; AS: Arterial stiffness; AIX: Augmentation index; CBP: Central aortic pressure; DD: Diastolic dysfunction; EF: Ejection fraction; HR: Heart rate; HDL: High-density lipoprotein; LV: Left ventricular; LVH: Left ventricular hypertrophy; LDL: Low-density lipoprotein; OBP: Office blood pressure; PP: Pulse pressure; PWV: Pulse wave velocity; TOD: Target organ damage; CH: Total cholesterol; TG: Triglycerides; WCH: White coat hypertension.

**References**
1. Cheng HM, Chuang SY, Wang TD, Kario K, Buranakitjaroen P, Chia YC et al (2020) Central blood pressure for the management of hypertension: is it a practical clinical tool in current practice? J Clin Hypertens 22:391–406
2. Cheng H-M, Park S, Huang Q, Hoshide S, Wang J-G, Kario K et al (2017) Vascular aging and hypertension: implications for the clinical application of central blood pressure. Int J Cardiol 230:209–213
3. Agabiti-Rosei E, Mancia G, O’Rourke MF, Roman MJ, Safar ME, Smulyan H et al (2007) Central blood pressure measurements and antihypertensive therapy: a consensus document. Hypertension 50(1):154–160
4. Laurent S, Cockerf J, Van Bortel L, Boutouyrie P, Giannattasio C, Hayoz D et al (2006) Expert consensus document on arterial stiffness: methodological issues and clinical applications. Eur Heart J 27:2588–2605
5. Ichihara A, Hayashi M, Koura Y, Tada Y, Hiroti N, Saruta T (2003) Long-term effects of intensive blood pressure lowering on arterial wall stiffness in hypertensive patients. Am J Hypertens. 16:959–965
6. Van Popele NM, Grobbee DE, Bots ML, Asmar R, Topouchian J, Reneman RS et al (2001) Association between arterial stiffness and atherosclerosis: the Rotterdam study. Stroke 32(2):454–460

7. Janić M, Lunder M, Šabovič M (2014) Arterial stiffness and cardiovascular risk in the young population. Arterioscler Thromb Vasc Biol 34(1):1–7

8. Dudenbostel T, Glasser SP (2012) Effects of antihypertensive drugs on arterial stiffness. Cardiol Rev 20(5):259–263

9. Vischer AS, Burkard T (2021) How should we measure and deal with office blood pressure in 2021? Diagnostics 11(2):235

10. Guaidine N (2019) Htn—nice. NICE Guideline. 2020

11. Williams B, Mancia G, Spiering W, Rosei EA, Azizi M, Burnier M et al (2018) 2018 practice guidelines for the management of arterial hypertension of the European society of cardiology and the European society of hypertension ESC/ESH task force for the management of arterial hypertension. J Hypertens. 36:2284–2309

12. The Mobil-O-Graph (2018) Operating manual. IEM GmbH, Stolberg.

13. Papaioannou TG (2019) Measurement of central augmentation index by the Mobil-O-Graph device: agreement among arteriograph, compiler, and Mobil-O-Graph devices. J Clin Hypertens 21:1386–92

14. Chi C, Yu X, Aucklee R, Lu Y, Fan X, Yu S et al (2017) Hypertensive target organ damage is better associated with central than brachial blood pressure: the Northern Shanghai Study. J Clin Hypertens. 19:1269–1275

15. Studinger P, Tabák AG, Chen CH, Salvi P, Othmane TEH, Torzsa P et al (2013) The Effect of low-dose carvedilol, nebivolol, and metoprolol on central arterial pressure and its determinants: a randomized clinical trial. J Clin Hypertens. 15:910–917

16. Kampus P, Serg M, Kali J, Zapora M, Muda P, Karu K et al (2011) Differential effects of nebivolol and metoprolol on central aortic pressure and left ventricular wall thickness. Hypertension. 57:1122–1128

17. Dhadam Z, McEniery CM, Yasmin Cockcroft JR, Brown MJ, Wilkinson IB (2006) Atenolol and eprosartan: differential effects on central blood pressure and aortic pulse wave velocity. Am J Hypertens 19(2):214–219. https://doi.org/10.1016/j.amjhy perf.2005.08.007

18. Morgan T, Lauri J, Bertram D, Anderson A (2004) Effect of different antihypertensive drug classes on central aortic pressure. Am J Hypertens. 17(2):118–123

19. Mahmud A (2007) Reducing arterial stiffness and wave reflection—quest for the Holy Grail? Artery Res 1(1):13–19

20. Protoegerou A, Stergiou G, Vlachopoulos C, Blacher J, Achimastos A (2009) The effect of antihypertensive drugs on central blood pressure beyond peripheral blood pressure. Part II: evidence for specific class-effects of antihypertensive drugs on pressure amplification. Curr Pharm Des. 15:272–289

21. Deary AJ, Schumann AL, Murfet H, Haydock SF, Foo RS-Y, Brown MJ (2002) Double-blind, placebo-controlled crossover comparison of five classes of antihypertensive drugs. J Hypertens. 20(4):771–777. https://doi.org/10.1097/00004872-200204000-00037

22. Manisty CH, Zambarlini A, Parker KH, Davies JE, Francis DP, Mayet J et al (2009) Differences in the magnitude of wave reflection account for differential effects of amlodipine- versus atenolol-based regimens on central blood pressure: an anglo-scandinavian cardiac outcome trial substudy. Hypertension 54(4):724–730

23. Ichihara A, Kaneshiro Y, Takemitsu T, Sakoda M (2006) Effects of amlodipine and valsartan on vascular damage and ambulatory blood pressure in untreated hypertensive patients. J Hum Hypertens. 20:787–794

24. Shi R, Liu K, Shi D, Liu Q, Chen X (2017) Effects of amlodipine and valsartan on blood pressure variability and pulse wave velocity in hypertensive patients. Am J Med Sci 353(1):6–11

25. Flack JM, Nasser SA (2011) Benefits of once-daily therapies in the treatment of hypertension. Vasc Health Risk Manag 7(1):777–787

26. Diaz A, Tringler M, Wray S, Ramirez AJ, Cabrera Fischer EI (2018) The effects of age on pulse wave velocity in untreated hypertension. J Clin Hypertens. 20:258–265

27. Cuomo F, Rocchabianca S, Dillon-Murphy D, Xiao N, Humphrey JD, Figueroa CA (2017) Effects of age-associated regional changes in arterial stiffness on human hemodynamics revealed by computational modeling. PLoS ONE 12:e0173177

28. Ando T, Okada S, Niijima Y, Hashimoto K, Shimizu H, Tsuchiya T et al (2010) Impaired glucose tolerance, but not impaired fasting glucose, is a risk factor for early-stage atherosclerosis. Diabet Med. 27:1430–1435

29. Rider OJ, Tayal U, Francis JM, Ali MK, Robinson NR, Byrne JP et al (2010) The effect of obesity and weight loss on aortic pulse wave velocity as assessed by magnetic resonance imaging. Obesity. 18:2311–6

30. Doonan RJ, Hausvater A, Scallan C, Mikhailidis DP, Pilote L, Daskalopoulou SS (2010) The effect of smoking on arterial stiffness. Hypertens Res. 33:398–410

31. Mahmud A, Feely J (2003) Effect of smoking on arterial stiffness and pulse pressure amplification. Hypertension. 41:183–187

32. Matsui Y, Kario K, Ishikawa J, Eguchi K, Hoshide S, Shimada K (2004) Reproducibility of arterial stiffness indices (pulse wave velocity and augmentation index) simultaneously assessed by automated pulse wave analysis and their associated risk factors in essential hypertensive patients. Hypertens Res. 27:851–857

33. Yasmin, Brown MJ (1999) Similarities and differences between augmentation index and pulse wave velocity in the assessment of arterial stiffness. QJM Mon J Assoc Physicians 92:595–600

34. Homan TD, Cichowski E (2019) Physiology, pulse pressure. StatPearls. StatPearls Publishing. Retrieved from http://www.ncbi.nlm.nih.gov/pubme...

35. Tang KS, Medeiros ED, Shah AD (2020) Wide pulse pressure: a clinical review. J Clin Hypertens (Greenwich) 22(11):1960–1967

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.